SAI MedPartners

Overview

SAI MedPartners is a life-sciences strategy consultancy for pharma, biotech, and medical-device teams. The buyer-facing profile is broader than classic competitive intelligence: SAI combines competitive intelligence, PharmaForce syndicated commercial benchmarking, Fulcrum market research, market access / pricing, and IDEA Pharma path-to-market positioning.

For launch teams, SAI is most useful when the hard question is how competitors are organized, how a therapy area is likely to move, how payer and access assumptions should shape strategy, and how the product should be positioned before major commercialization milestones. PharmaForce buyer intent should route here because PharmaForce International is now part of SAI, not a separate public vendor page.

The diligence issue is division fit. SAI can show up as competitive intelligence, PharmaForce benchmarking, market research, market access, or early asset positioning. The RFP should name which SAI division is doing the work, what data sources are being used, and whether the deliverables are strategic recommendations, syndicated benchmarks, custom primary research, or launch execution support.

Launch Capability Model

The framework below standardizes how Rx Almanac evaluates commercialization-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, SAI MedPartners is evaluated as life-sciences strategy consultancy for pharma, biotech, and medical-device teams.

Capability	Buyer should compare	SAI MedPartners readout
Integrated launch strategy	Launch objectives, segmentation, positioning, sequencing, governance, and cross-functional launch plan.	Major competitive intelligence. SAI’s public positioning centers on competitive intelligence and strategic insights for life-sciences companies. Documented via IDEA Pharma. IDEA Pharma adds positioning and path-to-market support for assets approaching critical development or launch milestones.
Commercial model and operating design	Org model, channel model, field model, vendor model, process design, and operating cadence.	PharmaForce strength. PharmaForce’s syndicated reports and Deployment Analyzer give SAI a concrete benchmarking lane.
Market access and patient-services orchestration	Coverage strategy, hub design, reimbursement support, affordability, and patient-services vendor coordination.	Access strategy. SAI markets a dedicated market access and pricing practice that connects payer strategy with competitive intelligence and market research. Documented via Fulcrum. Fulcrum Research Group is SAI’s healthcare market research division.
Analytics, forecasting, and opportunity sizing	Forecasts, market sizing, patient flow, targeting, launch KPIs, and scenario planning.	Not the main buying reason for SAI MedPartners; validate only if the SOW includes analytics, forecasting, and opportunity sizing.
Change management and implementation support	PMO, stakeholder alignment, implementation roadmaps, SOPs, training, and execution governance.	Validate scope. SAI is best read as intelligence and strategy-led; buyers should clarify where advisory stops and execution partners begin.
Portfolio and lifecycle strategy	Indication sequencing, lifecycle planning, portfolio tradeoffs, LOE, and expansion strategy.	Not the main buying reason for SAI MedPartners; validate only if the SOW includes portfolio and lifecycle strategy.

Buyer Fit

• Commercial fit trigger: Include SAI when launch strategy depends on competitor intelligence, commercial organization benchmarking, payer / pricing input, market research, or positioning.
• Best-fit questions: How are competitors deploying field, medical, market access, and marketing teams? How should the asset be positioned? Which payer and access assumptions should shape launch readiness?
• Therapy and product fit: Oncology, immunology, neurology, rare disease, hematology, endocrinology, biosimilars, specialty, biologics, cell / gene therapy, and other areas where field model and access strategy are tightly linked.
• Less ideal fit: Buyers seeking a CSO to staff reps, a hub operator, a specialty pharmacy, or a full agency execution partner without a strategy / intelligence workstream.
• Network diligence: Division ownership, senior-team involvement, source mix, data recency, geography, therapeutic scope, deliverable format, and whether outputs can be reused by brand, field, medical, and payer teams.

Differentiators

• PharmaForce commercial benchmarking: The acquired PharmaForce division gives SAI syndicated research and Deployment Analyzer data on competitor commercial operations.
• Intelligence-led access strategy: SAI’s market access / pricing work is explicitly connected to competitive intelligence and market research rather than isolated payer strategy.
• M&A-expanded platform: Fulcrum, PharmaForce, IDEA Pharma, and The Dunn Group broaden SAI beyond a single competitive-intelligence boutique.
• Early-to-peri-launch fit: IDEA Pharma and SAI’s broader strategy bench make the firm relevant before the product reaches full launch execution.
• Global life-sciences footprint: SAI markets offices across the U.S., Europe, and Asia, which matters for multi-market launch and benchmarking questions.

RFP Questions

• Which division will own the work: SAI core, PharmaForce, Fulcrum, IDEA Pharma, or The Dunn Group?
• Which inputs are primary interviews, syndicated reports, Deployment Analyzer data, desk research, or consultant judgment?
• How current is the benchmark data for the relevant therapy area, country, and competitor set?
• How can the team compare sales, field medical, MSL, market access, reimbursement, marketing, and target-audience structures?
• How will payer / pricing recommendations be reconciled with positioning, evidence, and competitor-response assumptions?
• Which deliverables can be handed to brand, medical, market access, field, and executive teams without rework?
• How will the project avoid conflating SAI’s PharmaForce International division with unrelated PharmaForce-named entities?

Recent Activity

• 2025: SAI announced The Dunn Group acquisition to deepen competitive-intelligence and pipeline-analysis capabilities.
• 2024: SAI acquired IDEA Pharma, adding path-to-market and positioning strategy.
• 2024: SAI added Fulcrum Research Group, expanding custom healthcare market research.
• 2023: SAI acquired PharmaForce International, adding syndicated commercial operations benchmarking and Deployment Analyzer buyer intent.
• 2022: Northlane Capital Partners invested in SAI MedPartners to support platform expansion and acquisition-led growth.